Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 9086 results
Found 9086 results.

Adult

Robertson K, Kumwenda J, Supparatpinyo K, et al. "A multinational study of neurological performance in antiretroviral therapy-naïve HIV-1-infected persons in diverse resource-constrained settings." J. Neurovirol.. 2011;17(5):438-47.
Albrecht M, A Mukherjee L, Tierney C, et al. "A randomized clinical trial evaluating therapeutic drug monitoring (TDM) for protease inhibitor-based regimens in antiretroviral-experienced HIV-infected individuals: week 48 results of the A5146 study." HIV Clin Trials. 2011;12(4):201-14.
Kalayjian RC, Wu K, Evans S, et al. "Proteinuria is associated with neurocognitive impairment in antiretroviral therapy treated HIV-infected individuals." J. Acquir. Immune Defic. Syndr.. 2014;67(1):30-5.
Behler CM, Vittinghoff E, Lin F, et al. "Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1-coinfected subjects." Clin. Infect. Dis.. 2007;44(10):1375-83.
Swindells S, Komarow L, Tripathy S, et al. "Screening for pulmonary tuberculosis in HIV-infected individuals: AIDS Clinical Trials Group Protocol A5253." Int. J. Tuberc. Lung Dis.. 2013;17(4):532-9.
Shivakoti R, Yang W-T, Berendes S, et al. "Persistently Elevated C-Reactive Protein Level in the First Year of Antiretroviral Therapy, Despite Virologic Suppression, Is Associated With HIV Disease Progression in Resource-Constrained Settings." J. Infect. Dis.. 2016;213(7):1074-8.
Gulick RM, Wilkin TJ, Chen YQ, et al. "Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial." Ann. Intern. Med.. 2017;167(6):384-393.
Lok JJ, Bosch RJ, Benson CA, et al. "Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection." AIDS. 2010;24(12):1867-76.
Krishnan S, Schouten JT, Atkinson B, et al. "Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naive HIV-infected individuals." J. Acquir. Immune Defic. Syndr.. 2012;61(3):381-9.
Sherman KE, Andersen JW, Butt AA, et al. "Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAM-C)." J. Acquir. Immune Defic. Syndr.. 2010;55(5):597-605.
Hulgan T, Donahue JP, Smeaton L, et al. "Oral cyclosporin A inhibits CD4 T cell P-glycoprotein activity in HIV-infected adults initiating treatment with nucleoside reverse transcriptase inhibitors." Eur. J. Clin. Pharmacol.. 2009;65(11):1081-8.
Lockman S, Hughes MD, McIntyre J, et al. "Antiretroviral therapies in women after single-dose nevirapine exposure." N. Engl. J. Med.. 2010;363(16):1499-509.
Mrus JM, Schackman BR, Wu AW, et al. "Variations in self-rated health among patients with HIV infection." Qual Life Res. 2006;15(3):503-14.
Aweeka FT, Kang M, Yu J-Y, Lizak P, Alston B, Chung RT. "Pharmacokinetic evaluation of the effects of ribavirin on zidovudine triphosphate formation: ACTG 5092s Study Team." HIV Med.. 2007;8(5):288-94.
Palermo B, Bosch RJ, Bennett K, Jacobson JM. "Body mass index and CD4+ T-lymphocyte recovery in HIV-infected men with viral suppression on antiretroviral therapy." HIV Clin Trials. 2011;12(4):222-7.
Gulick RM, Ribaudo HJ, Shikuma CM, et al. "Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial." JAMA. 2006;296(7):769-81.
Ofotokun I, Na LH, Landovitz RJ, et al. "Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257." Clin. Infect. Dis.. 2015;60(12):1842-51.

Africa

Bartlett JA, Ribaudo HJ, Wallis CL, et al. "Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings." AIDS. 2012;26(11):1345-54.
Robertson K, Kopnisky K, Hakim J, et al. "Second assessment of NeuroAIDS in Africa." J. Neurovirol.. 2008;14(2):87-101.
Kumarasamy N, Aga E, Ribaudo HJ, et al. "Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230." Clin. Infect. Dis.. 2015;60(10):1552-8.
Grinsztejn B, Smeaton L, Barnett R, et al. "Sex-associated differences in pre-antiretroviral therapy plasma HIV-1 RNA in diverse areas of the world vary by CD4(+) T-cell count." Antivir. Ther. (Lond.). 2011;16(7):1057-62.
Lockman S, Hughes M, Sawe F, et al. "Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial." PLoS Med.. 2012;9(6):e1001236.
Asmelash A, Zheng Y, Kaloustian KWools, et al. "Predictors of suboptimal CD4 response among women achieving virologic suppression in a randomized antiretroviral treatment trial, Africa." BMC Infect. Dis.. 2014;14:331.
Safren SA, Hendriksen ES, Smeaton L, et al. "Quality of life among individuals with HIV starting antiretroviral therapy in diverse resource-limited areas of the world." AIDS Behav. 2012;16(2):266-77.
Firnhaber C, Smeaton L, Saukila N, et al. "Comparisons of anemia, thrombocytopenia, and neutropenia at initiation of HIV antiretroviral therapy in Africa, Asia, and the Americas." Int. J. Infect. Dis.. 2010;14(12):e1088-92.
Greer AE, San Ou S-, Wilson E, et al. "Comparison of Hepatitis B Virus Infection in HIV-Infected and HIV-Uninfected Participants Enrolled in a Multinational Clinical Trial: HPTN 052." J. Acquir. Immune Defic. Syndr.. 2017;76(4):388-393.

Pages